The human oesophagus is home to a complex microbial community, the oesophageal microbiome.
Altering the microbiome for immunotherapy-resistant urological tumors-An intriguing but still early concept
The intestinal microbiome may play an important role in immunomodulation and affect treatment responses to immune checkpoint inhibitor therapy in genitourinary malignancies.
Fecal microbiota transplantation for immunotherapy-resistant urological tumors: Is it time? An update of the recent literature
It is time for fecal microbiota transplantation to be suggested and tested in urological tumors resistant to immune checkpoint inhibitors. Clinical trials and investigations are ongoing in this field.
Antibiotics Use and Subsequent Risk of Colorectal Cancer: A Swedish Nationwide Population-Based Study
Antibiotics use may increase colorectal cancer (CRC) risk by altering the gut microbiota, with suggestive evidence reported. Our study aims to investigate antibiotics use in relation to subsequent CRC risk.
Multiple sclerosis (MS) is a demyelinating disease that affects young adults; in that age group, it represents the second leading cause of disability in our setting.
The gut microbiota is well known to exert multiple benefits on human health including protection from disease causing pathobiont microbes.
New research from SAHMRI and Flinders University has shown myelosuppressive chemotherapy destabilises gut microbiome in patients with solid organ cancers.
Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4 and PD-1 is associated with clinical benefit across tumor types, but also a high rate of immune-related adverse events.
A synthetic consortium of 100 gut commensals modulates the composition and function in a colon model of the microbiome of elderly subjects
Administration of cultured gut isolates holds promise for modulating the altered composition and function of the microbiota in older subjects, and for promoting their health.